Guilford Pharmaceuticals Appoints Senior Executive

Baltimore (ots-PRNewswire) - Guilford Pharmaceuticals Inc.
(Nasdaq: GLFD) today announced the appointment of David H. Bergstrom, Ph.D., as Vice President, Pharmaceutical and Chemical Development.

Dr. Bergstrom joins Guilford from Hoechst Marion Roussel, Inc., where for the past two years he was Director of Pharmaceutical & Analytical Sciences after serving for 5 years as Director of Pharmaceutical Development for the predecessor company Hoechst-Roussel Pharmaceuticals Inc. He was responsible for managing the research and development effort in order to facilitate optimal lead candidate selection and position it for eventual commercial development. Prior to joining Hoechst Marion Roussel, he worked at CIBA Geigy in Pharmaceutical Development.

"We are very pleased to have been able to retain such an experienced and capable person as Dr. David Bergstrom. David will be responsible for leading Guilford's efforts in formulation development, process development, chemical development, and analytical chemistry. With the addition of this position, we have now completed the building of our senior management team in drug development, and are well positioned to move forward in our corporate strategic goal to maximize the efficiency with which we progress promising new drugs through the development process", commented Dr. Craig R. Smith, Guilford's President and C.E.O.

Dr. Bergstrom received his Ph.D. in Pharmaceutics at the University of Utah in 1985. In addition, he received his M.S. in Pharmaceutical Chemistry at the University of Michigan in 1982 and his B.S. degree in Pharmacy in 1978 at Ferris State University. Dr. Bergstrom is a member of the Pharmaceutical Research and Manufacturers Association and currently is Chairman of the Pharmaceutical Development Steering Committee. Other affiliations include the American Association of Pharmaceutical Scientists, Controlled Release Society, Drug Information Association, Parenteral Drug Association, Phi Lambda Upsilon

Guilford Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development of polymer-based therapeutics for brain and other cancers, and novel products for the diagnosis and treatment of neurological diseases, including Parkinson's Disease, Alzheimer's disease, stroke, head trauma, spinal cord injuries, multiple sclerosis, peripheral neuropathies and cocaine addiction.

ots Original Text Service: Guilford Pharmaceuticals, Inc.

CONTACT: Angela Rubin of Guilford Pharmaceuticals Inc.,
USA: 410-631-6449; or for media: Brad Miles, or for investors:
Jonathan Fassberg, both for Guilford Pharmaceuticals, Inc., USA:
212-477-9007 Web site:

Rückfragen bitte an News Aktuell Tel.: +49 40 4113-2856